MAP2K7 and central nervous system cancer: BRAFV600E and MEK inhibitor combination therapy (e.g., dabrafenib+trametinib) has been tested in the clinic against glioma and clinical response rates of 70% and 33% have been observed amongst adults with low- and high-grade glioma, respectively.